| abstract |
REFERS TO IMIDAZOLE DERIVATIVES OF FORMULA I WHERE A IS PHENYL, PIRIDIN-2-IL, PIRIDIN-3-IL, PIPERIDIN-1-IL; R1 AND R2 ARE H, HALOGEN, ALKYL, CYCLOALKYL, ALKENYL, TRIFLUOROMETHYL, O-TRIFLUOROMETHYL, AMONG OTHERS; R3 IS H, ALKYL, CYCLOALKYL, PHENYL, S-ALKYL, AMINO, AMONG OTHERS; R4 AND R5 ARE H, ALKYL OR TOGETHER WITH C FORMAN (CH2) 4; R6 AND R6 'ARE H, ALKYL; X IS N, C =, Y ES = N, NH, N = CH, CH =; Z IS CR7 =, N =, NR7, N = CR7, AMONG OTHERS; R7 IS H, CH2OH, ALKYL; n IS 0-2; m IS 0-1. PREFERRED COMPOUNDS ARE 1H-IMIDAZOLE, 1 - [[1- (4-CHLORO-3-METHYLPHENYL) -1H-IMIDAZOL-4-IL] METHYL] -2-ETHYL; 1H-IMIDAZOLE, 1 [[1- (4-CHLORO-3-METHYLPHENYL) -1H-IMIDAZOL-4-IL] METHYL] -2-METHYL; 1- (3,4-DICHLORO-PHENYL) -3- (2-METHYL-IMIDAZOL-1-IL-METHYL) -1H-PIRAZOLE, AMONG OTHERS. IT ALSO REFERS TO A PROCEDURE FOR PREPARATION. THE COMPOUNDS ARE SPECIFIC BLOCKERS OF A SUBTYPE OF N-METHYL-D-ASPARATE NMDA RECEPTOR AND MAY BE USEFUL FOR THE TREATMENT OF NEURODEGENERATION, ALZHEIMER'S DISEASE, PARKINSON, HUNTINGTON, LATERAL INFLUENCE OF AMYOTROCIDIC BREEDING INFLUENCES, LATERAL BLOOD SCLEROSIS |